Clin2
NCT07146503Likely a fitRecruiting

Esketamine Nasal Spray for Treatment-Resistant Depression in Real Life

Depression and Quality of LifeTreatment Resistant Depression (TRD)AnhedoniaApathyAnxietyCognitionTemperamentPsychiatric Comorbidities

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This study tests esketamine nasal spray (a fast-acting antidepressant) for people with treatment-resistant depression who haven't gotten better after trying at least two other antidepressants. It looks at how well the spray works in everyday doctor's offices, not just in research clinics.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years to 74 years
Study type
Observational

Who can take part

  • You are between 18 and 74 years old.
  • You have been diagnosed with a major depressive episode (a period of severe depression).
  • You have tried at least two different antidepressant treatments that didn't help enough.
  • You are currently taking an SSRI or SNRI (antidepressant medications like Prozac, Zoloft, or Effexor) and your doctor thinks esketamine nasal spray is a good option for you.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07369102Recruiting· Phase 4
Esketamine with or without talk therapy for tough depression

This trial tests if adding a type of talk therapy called integration therapy helps esketamine work better for people with depression that hasn't improved with other treatments. You'll receive esketamine, and some people also get guided sessions to reflect on their experiences.

San Juan
NCT06668571Recruiting· Phase 2
Ketamine for treatment-resistant depression

This study tests if intravenous ketamine can help people with treatment-resistant depression who haven't found relief from at least two other treatments. If you qualify, you'll receive ketamine infusions to see if it improves your mood.

Rochester, Minnesota
NCT05973851Recruiting· Phase 3
Six-week medicine boost for depression after first treatment failure

This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.

Innsbruck
NCT07716098Recruiting· Phase 3
Esketamine nasal spray for treatment-resistant depression

This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.

Redlands, California
NCT06103760Recruiting· Phase 4
Esketamine for hard-to-treat depression

This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.

St Leonards, New South Wales
NCT06488586Recruiting
Ketamine vs Esketamine for treatment-resistant depression

This trial compares two forms of ketamine—given by IV or as a nasal spray—in people with major depression that hasn't improved after trying at least two other antidepressants. The goal is to see which treatment works better.

Kingston, Ontario

Hear when a new Depression and Quality of Life trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.